

10/532371

Rec'd PCT/PTC 21 APR 2005

Atty. Docket No. 127USw
US National Phase of PCT/EP2003/01664

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Desmond John BEST et al.

Serial No.: To be Assigned

Filing Date: Concurrently Herewith

For: Aryloxyalkylamine Derivatives as H3 Receptor Ligands

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Copies of the references are enclosed
 Copies of the references were submitted in parent application Serial No. _____.
(37 CFR 1.98(d))
 A copy of the International Search Report which issued on International Application No. PCT/EP2003/01164 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

Express Mail Label No.: EV332065624US

Date of Mailing: 4/21/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

Patty Wilson
Patty Wilson

10/532371

Atty. Docket No. 127USw
US National Phase PCT/EP2003/01664

JCP Rec'd PCT/PTC 21 APR 2005

[] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

[] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]


[] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

[] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,



James P. Riek
Attorney of Record
Registration No. 39,009

Date: 4-21-05

Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8022
Facsimile: (919) 483-7988

10/532371

J Rec'd PCT/PTC 21 APR 2005

Page 1 of 1

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		SERIAL NO.	To be assigned
		FILING DATE	Concurrently herewith
		APPLICANT	Desmond John BEST
		GROUP	
		EXAMINER	
		ATTORNEY DOCKET NO.	P33127USw

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	1.	WO02076925	10/3/2002	PCT			
	2.	WO0212190	2/14/2002	PCT			
	3.	WO0006254	2/10/2000	PCT			
	4.	WO0166534	9/13/2001	PCT			
	5.	WO0240466	5/23/2002	PCT			
	6.	WO03004480	1/16/2003	PCT			

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

	7.	CARLING et al., "1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A Selective High-Affinity Antagonist for the Human Dopamine D ₄ Receptor with Excellent Selectivity over Ion Channels" J. Med Chem 42:2706-2715 (1999).
	8.	CAROON et al., "Synthesis and Antihypertensive Activity of a Series of 8-Substituted 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones" J. Med Chem 24:1320-1328 (1981).
	9.	CLARK et al., "Antihypertensive 9-Substituted 1-Oxa-4,9-diazaspiro[5.5]undecan-3-ones", J. Med Chem 26:855-861 (1983).
	10.	GIOVANNINI et al., "Effects of histamine H ₃ receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia," Behavirural Brain Res. 104:147-155 (1999).
	11.	LEURS et al., "Therapeutic potential of histamine H ₃ receptor agonists and antagonists," TiPS 19:177-183 (May 1998).
	12.	LOVENBERG et al., "Cloning and Funcational Expression of the Human Histamine H ₃ Receptor," Molecular Pharmacology 55:1101-1107 (1999).
	13.	ONODERA and WATANABE, "Histamine H ₃ Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).
	14.	SCHLICKER et al., "Modulation of neurotransmitter release via histamine H ₃ heteroreceptors," Fundam Clin Pharmacol 8:128-137 (1994).
	15.	SMITH et al., "New Spiropiperidines as Potent and Selective Non-Peptide Tachykinin NK ₂ Receptor Antagonists", J. Med. Chem 38:3772-3779 (1995).
	16.	WALSH et al., "Synthesis and Antiallergy Activity of 4-(Diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and Structurally Related Compounds," J. Med. Chem 32:105-118 (1989).

Continue on page

EXAMINER	/Noble Jarrell/ (02/13/2008)	DATE CONSIDERED
-----------------	------------------------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./ (02/13/2008)